Starling Oncology Executive and Leadership Team

Paul Johnson, the Chief Executive Officer at Starling Oncology, directs the overarching strategic vision for the organization. Johnson architects the long-term growth trajectory by expanding the value-based cancer care delivery model across North American markets. By aligning clinical excellence with operational efficiency, the Chief Executive Officer ensures the network of clinics maintains high standards for evidence-based oncology treatments. This leadership role involves constant collaboration with the Board to secure resources for clinical trials and transfusion services. Paul Johnson drives the integration of patient care pathways to optimize health outcomes for communities served. Through rigorous oversight of corporate initiatives, the Chief Executive Officer fosters a culture of innovation and accountability. Ultimately, Johnson secures the financial and operational health of the enterprise while positioning the organization as a leader in the oncology healthcare services sector.

Robert Carter, the Chief Financial Officer at Starling Oncology, governs the fiscal health and capital allocation strategies of the organization. Carter architects robust financial frameworks that support the expansion of value-based cancer care services. By monitoring revenue cycles and cost structures, the Chief Financial Officer ensures the sustainability of the integrated care delivery model. This leadership role involves managing investor relations and providing data-driven insights to the executive team regarding market performance. Robert Carter drives the financial planning necessary for investing in clinical trials and advanced medical equipment. Through meticulous oversight of budgetary compliance, the Chief Financial Officer mitigates fiscal risks while maximizing resource utilization across the clinic network. Ultimately, Carter secures the long-term economic stability required to maintain high-quality oncology services for all patients.

Daniel Virnich, the Chief Operating Officer at Starling Oncology, manages the daily execution of clinical operations and service delivery. Virnich optimizes the workflow within the network of clinics to ensure seamless patient access to transfusions and specialized oncology treatments. Overseeing the operational infrastructure, the Chief Operating Officer implements standardized protocols that enhance the efficiency of the integrated cancer care delivery model. This role requires constant coordination with regional leadership to maintain consistent service quality across all facilities. Daniel Virnich drives the adoption of new clinical technologies to streamline administrative burdens for medical staff. By focusing on operational scalability, the Chief Operating Officer supports the expansion of the company footprint. Ultimately, Virnich ensures that every clinic functions at peak performance to deliver superior value-based care to patients.

Dan Ayer, the Regional President at Starling Oncology, directs the operational success of clinics within assigned geographic territories. Ayer architects localized strategies to increase patient access to oncology services and clinical trials. By managing regional performance metrics, the Regional President ensures that every clinic adheres to the corporate value-based care standards. This leadership role involves building strong relationships with local healthcare providers and community stakeholders to expand the network reach. Dan Ayer drives the implementation of operational improvements that enhance patient satisfaction and clinical outcomes. Through active oversight of regional resources, the Regional President optimizes the delivery of transfusions and specialized treatments. Ultimately, Ayer secures the competitive position of the organization within the regional market by maintaining operational excellence and fostering growth.

Kiran Annavarapu, the Market President at Starling Oncology, oversees the growth and performance of specific oncology service markets. Annavarapu architects market-entry strategies that align with the broader organizational goal of providing value-based cancer care. By analyzing local healthcare trends, the Market President identifies opportunities to integrate new clinics and affiliated providers into the network. This role involves managing the day-to-day business operations and ensuring that clinical teams meet performance targets. Kiran Annavarapu drives the development of partnerships with local health systems to enhance the patient care delivery model. Through consistent monitoring of market dynamics, the Market President adjusts operational tactics to maintain high service standards. Ultimately, Annavarapu secures the market share and operational viability of the organization within the assigned territory.

Stacy Constantine, the Regional President at Starling Oncology, manages the strategic operations and clinical service delivery across designated regions. Constantine architects initiatives that improve the efficiency of the integrated cancer care model within these areas. By overseeing the performance of multiple clinics, the Regional President ensures that evidence-based treatments and clinical trials remain accessible to the community. This leadership role involves coordinating with the Chief Medical Officer to maintain high clinical standards. Stacy Constantine drives the expansion of transfusion services and patient support programs to meet regional demand. Through rigorous management of regional budgets and staffing, the Regional President optimizes the quality of care provided. Ultimately, Constantine secures the operational success and growth of the organization by fostering strong clinical outcomes and patient-centered service delivery.

Yale Podnos, the Chief Medical Officer at Starling Oncology, leads the clinical strategy and ensures the delivery of evidence-based oncology treatments. Podnos architects the medical protocols that define the value-based care model across the entire network of clinics. Overseeing the clinical trials program, the Chief Medical Officer maintains rigorous standards for patient safety and therapeutic efficacy. This role involves mentoring affiliated providers and fostering a culture of continuous medical education. Yale Podnos drives the integration of specialized transfusion services into the broader patient care framework. By collaborating with other C-suite leaders, the Chief Medical Officer aligns clinical objectives with the overall business mission. Ultimately, Podnos ensures that the organization remains at the forefront of oncology innovation while providing compassionate, high-quality care to every patient.